These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 21814144

  • 1. A longitudinal cohort study of mucocutaneous drug eruptions during interferon and ribavirin treatment of hepatitis C.
    Tavakoli-Tabasi S, Bagree A.
    J Clin Gastroenterol; 2012 Feb; 46(2):162-7. PubMed ID: 21814144
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.
    Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J, Kyushu University Liver Disease Study [KULDS] Group.
    J Gastroenterol Hepatol; 2012 Jul; 27(7):1233-40. PubMed ID: 22098185
    [Abstract] [Full Text] [Related]

  • 3. Etanercept as prophylactic psoriatic therapy before interferon-alpha and ribavirin treatment for active hepatitis C infection.
    Behnam SE, Hindiyeh R, Fife DJ, Jeffes EW, Wu JJ.
    Clin Exp Dermatol; 2010 Jun; 35(4):397-8. PubMed ID: 19663835
    [Abstract] [Full Text] [Related]

  • 4. Predictive factors for adverse dermatological events during pegylated/interferon alpha and ribavirin treatment for hepatitis C.
    Li Z, Zhang Y, An J, Feng Y, Deng H, Xiao S, Ji F.
    J Clin Virol; 2014 Jul; 60(3):190-5. PubMed ID: 24830933
    [Abstract] [Full Text] [Related]

  • 5. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK, Bansal SB, Gupta A, Gulati S, Kumar A, Prasad N.
    Clin Transplant; 2006 Jul; 20(6):677-83. PubMed ID: 17100715
    [Abstract] [Full Text] [Related]

  • 6. Multiple fixed drug eruption with interferon/ribavirin combination therapy for hepatitis C virus infection.
    Sidhu-Malik NK, Kaplan AL.
    J Drugs Dermatol; 2003 Oct; 2(5):570-3. PubMed ID: 14558408
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus.
    Hashimoto Y, Kanto H, Itoh M.
    J Dermatol; 2007 Aug; 34(8):577-82. PubMed ID: 17683392
    [Abstract] [Full Text] [Related]

  • 11. [Cutaneous adverse events of telaprevir/peginterferon/ribavirin therapy for chronic hepatitis C: A multicenter prospective cohort study].
    Lorcy S, Gaudy-Marqueste C, Botta D, Portal I, Quiles N, Oulies V, Mancini J, Grob JJ, Richard MA.
    Ann Dermatol Venereol; 2016 May; 143(5):336-46. PubMed ID: 27161648
    [Abstract] [Full Text] [Related]

  • 12. [Generalized eczema secondary to combined treatment with peginterferon alfa-2a and ribavirin in a patient with chronic hepatitis from the hepatitis C virus].
    Ruiz de Casas A, García-Bravo B, Camacho F.
    Actas Dermosifiliogr; 2005 Mar; 96(2):122-3. PubMed ID: 16476350
    [Abstract] [Full Text] [Related]

  • 13. Allergic sensitization to pegylated interferon-α results in drug eruptions.
    Meller S, Gerber PA, Kislat A, Hevezi P, Göbel T, Wiesner U, Kellermann S, Bünemann E, Zlotnik A, Häussinger D, Erhardt A, Homey B.
    Allergy; 2015 Jul; 70(7):775-83. PubMed ID: 25831972
    [Abstract] [Full Text] [Related]

  • 14. Modifications of haematological series in patients co-infected with human immunodeficiency virus and hepatitis C virus during treatment with interferon and ribavirin: differences between pegylated and standard interferon.
    Arizcorreta A, Brun F, Fernández-Gutiérrez C, García Juárez R, Guerrero F, Pérez-Guzmán E, Girón-González JA.
    Clin Microbiol Infect; 2004 Dec; 10(12):1067-74. PubMed ID: 15606633
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cutaneous reactions in patients with chronic hepatitis C treated with peginterferon and ribavirin.
    Patrk I, Morović M, Markulin A, Patrk J.
    Dermatology; 2014 Dec; 228(1):42-6. PubMed ID: 24434490
    [Abstract] [Full Text] [Related]

  • 18. Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C.
    Yurci A, Guven K, Torun E, Gursoy S, Baskol M, Akgun H, Ozbakir O, Yucesoy M.
    Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):811-5. PubMed ID: 17700270
    [Abstract] [Full Text] [Related]

  • 19. Pattern and associated factors of anti-hepatitis C virus treatment-induced adverse reactions.
    Ravi S, Nasiri-Toosi M, Karimzadeh I, Khalili H, Ahadi-Barzoki M, Dashti-Khavidaki S.
    Expert Opin Drug Saf; 2014 Mar; 13(3):277-86. PubMed ID: 24386997
    [Abstract] [Full Text] [Related]

  • 20. Severe, generalized nummular eczema secondary to interferon alfa-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection.
    Moore MM, Elpern DJ, Carter DJ.
    Arch Dermatol; 2004 Feb; 140(2):215-7. PubMed ID: 14967798
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.